Get started
Work

Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study

Year: 2018
Type: article
Study design: Clinical Trial
Abstract: Background: Subsequent treatment with ipi offers 10-13% ORR (Bowyer 2016, Long 2016) in aPD1 refractory MM. Tilsotolimod, a synthetic TLR9 agonist oligonucleotide, acts on macrophages and dendritic cells to alter the tumor microenvironment. Local drug-induced type 1 interferon response results in increased antigen presentation and downstream T cell activation and proliferation in injected and non-injected lesions (Haymaker, SITC 2017).
DOI: 10.1093/annonc/mdy289.001
Authors: A. Diab, C. Haymaker, C. Bernatchez, R.H.I. Andtbacka, M. Shaheen, D. Johnson, J. Markowitz, I. Puzanov, R. Murthy, D.H. Johnson, M. James, S. Chunduru, J. Geib, S. Swann, S. Rahimian, P. Hwu
Institutions: The University of Texas MD Anderson Cancer Center, Huntsman Cancer Institute, University of Arizona Cancer Center, Vanderbilt University, Moffitt Cancer Center, Roswell Park Comprehensive Cancer Center, Idera Pharmaceuticals (United States)
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2895839418
FWCI: 1.043
Cites:
Cited by: 14
Related to: 10